Human IgG1 (N298A) Control Antibody

Monoclonal human IgG1 (N298A) antibody against E. coli β-galactosidase

Anti-β-Gal-hIgG1 (N298A) features the constant region of the human IgG1 (N298A) isotype and the variable region targeting E. coli's β-galactosidase (β-Gal), an antigen that is not present in mice.

This antibody was generated by DNA immunization with a plasmid expressing the β-Gal gene in Swiss mice.

Anti-β-Gal-hIgG1 (N298A) can be used as an isotype control for human IgG1 antibodies containing the N298A mutation. Antibodies with this mutation contain a modified Fc region designed to limit antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [1, 2], as this mutation eliminates their ability to bind to human Fcγ receptors.

Anti-β-Gal-hIgG1 (N298A) was generated by recombinant DNA technology. It has been produced in Chinese hamster ovary (CHO) cells and purified by affinity chromatography with protein G.

References:

1. Spigel D. et al., 2013. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [ASCO abstract 8008]. J Clin Oncol. 31(15)(suppl).
2. Herbst RS. et al., 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515(7528):563-7.